or Try an Advanced Search...

    ETF Components for LABD - Direxion Daily S&P Biotech Bear 3X Shares


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    EXEL A 1.80 1.91
    BMRN A -0.93 1.89
    BLUE F -4.91 1.87
    VRTX C -1.02 1.84
    SAGE F 8.11 1.80
    UTHR A 1.08 1.78
    REGN C -0.09 1.77
    AMGN C -0.19 1.75
    ALNY F -1.55 1.73
    EXAS D -0.46 1.73
    ABBV C -1.03 1.72
    ACAD F -0.90 1.68
    SRPT C 6.09 1.66
    BIIB D 4.56 1.65
    IONS D 1.46 1.64
    GILD F 0.07 1.64
    NBIX B -0.80 1.62
    BPMC B -0.03 1.61
    INCY F 0.17 1.51
    RARE D -1.84 1.49
    MRNA A 0.89 1.47
    LGND B 1.59 1.46
    ARWR F -2.06 1.45
    BHVN D -2.25 1.42
    PTCT F -0.79 1.40
    FOLD F -1.59 1.38
    AGIO A -0.44 1.37
    APLS F 2.48 1.24
    ALKS D 1.61 1.21
    MYGN F 0.16 1.08
    NTRA A 0.51 1.08
    IOVA D -1.26 1.07
    FGEN F -8.01 1.05
    RGNX F 0.88 1.05
    DCPH D -0.34 1.01
    CHRS F -7.34 0.99
    EBS F -4.80 0.96
    CDNA F -3.04 0.93
    HRTX B -5.36 0.84
    INSM D 2.14 0.81
    KPTI F 0.00 0.79
    ESPR C 1.91 0.79
    ALLK F -2.86 0.76
    IRWD D -2.53 0.75
    VCYT D 0.35 0.72
    HALO C 0.38 0.71
    FATE D -5.29 0.67
    EDIT F -2.01 0.66
    PBYI D -5.85 0.65
    MDGL D -6.29 0.59
    TGTX D -1.89 0.55
    ADVM F -7.36 0.55
    ALLO F -9.79 0.54
    CPRX D 2.65 0.53
    ANAB F 0.47 0.53
    XNCR F 3.54 0.49
    SGMO F -5.36 0.48
    ENTA D -1.75 0.47
    EGRX F -4.61 0.42
    GTHX B -4.77 0.42
    ATRA F -0.54 0.41
    VKTX D 0.22 0.38
    ANIK A 0.43 0.37
    VNDA B -1.51 0.35
    OPK C -1.60 0.35
    VCEL D -0.67 0.34
    TVTX F -5.05 0.33
    KOD F 1.50 0.29
    BBIO F -1.69 0.29
    NTLA F -1.67 0.29
    PGEN C 1.43 0.29
    DNLI F -3.41 0.28
    KRYS B -1.85 0.28
    GOSS F -3.97 0.27
    VYGR F -1.05 0.26
    MGNX D -3.27 0.25
    ALEC F -1.69 0.25
    CYTK D 1.91 0.25
    DVAX F -2.89 0.24
    YMAB C -0.33 0.24

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Biotechnology Medicine Cancer Life Sciences Clinical Development Biology Chemical Compounds Inflammation Clinical Medicine Disease Immune System Immunology S&P 500 Cholesterol Genetics Infectious Diseases Monoclonal Antibody Nasdaq 100 Organ Systems
    Industries: Biotechnology Drug Manufacturers - Specialty & Generic Drug Manufacturers - Major Diagnostics & Research

    Recent News for Direxion Daily S&P Biotech Bear 3X Shares & its Holdings

    Date Stock Title
    Apr 24 VKTX Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcript
    Apr 24 NBIX Neurocrine launches CAH community website ahead of FDA filing
    Apr 24 BMRN BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
    Apr 24 VKTX Viking Therapeutics down 4% despite quarterly bottom line beat
    Apr 24 BIIB Why Biogen Stock Leaped Nearly 5% Higher Today
    Apr 24 EXAS Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note
    Apr 24 VNDA Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know
    Apr 24 VKTX Viking Therapeutics Reports First Quarter 2024 Results: Aligns with Analyst Projections
    Apr 24 BMRN BioMarin Pharmaceutical Inc. (BMRN) Q1 2024 Earnings: Surpasses Revenue and EPS Estimates
    Apr 24 BMRN BioMarin updated 2024 guidance sees EPS raise, but no change to revenue
    Apr 24 PTCT PTC Therapeutics Q1 2024 Earnings Preview
    Apr 24 VKTX Viking Therapeutics Reports Q1 Results: 'An Exceptional Period' Says CEO
    Apr 24 BMRN BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
    Apr 24 ABBV AbbVie breaks six day winning cycle, trades in the red
    Apr 24 VKTX Viking Therapeutics GAAP EPS of -$0.26 beats by $0.02
    Apr 24 DVAX Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
    Apr 24 VKTX Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    Apr 24 ACAD Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
    Apr 24 BMRN BioMarin Pharmaceutical Non-GAAP EPS of $0.71 beats by $0.11, revenue of $648.83M misses by $2.98M
    Apr 24 BMRN BioMarin Reports Record Financial Results for the First Quarter 2024
    The investment seeks daily investment results, before fees and expenses, of 300% of the inverse of the performance of the S&P Biotechnology Select Industry Index. The index is provided by Standard & Poor's and includes domestic companies from the biotechnology industry. The fund normally creates short positions by investing at least 80% of its assets in: swap agreements; options on securities and indices; forward contracts; short positions; reverse repurchase agreements; ETFs; and other financial instruments that, in combination, provide inverse leveraged and unleveraged exposure to the S&P Biotechnology Select Industry Index ("index"). It is non-diversified.
    Exchange Traded Fund ETF Exchange Traded Funds Biotechnology Leveraged ETF Ultra ETF S&P 500 Index CBOE Inverse ETF Bear Market ETF Repurchase Agreement Financial Regulation Forward Contract
    Back to the Main LABD Page...